Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review
Open accessThe DOI matches its Crossref record; 175 of the 177 references it cites were found in a registry or an index.
Abstract
Accumulating evidence regarding clinical, neurobiological, genetic, and environmental factors suggests a bidirectional link between obesity and depressive disorders. Although a few studies have investigated the link between obesity/excess body weight and the response to antidepressants in depressive disorders, the effect of weight on treatment response remains poorly understood. In this review, we summarized recent data regarding the relationship between the response to antidepressants and obesity/excess body weight in clinical studies of patients with depressive disorders. Although several studies indicated an association between obesity/excess body weight and poor antidepressant responses, it is difficult to draw definitive conclusions due to the variability of subject composition and methodological differences among studies. Especially, differences in sex, age and menopausal status, depressive symptom subtypes, and antidepressants administered may have caused inconsistencies in the results among studies. The relationship between obesity/excess body weight and antidepressant responses should be investigated further in high-powered studies addressing the differential effects on subject characteristics and treatment. Moreover, future research should focus on the roles of mediating factors, such as inflammatory markers and neurocognitive performance, which may alter the antidepressant treatment outcome in patients with comorbid obesity and depressive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760 · cited 1×
“In addition, adipose tissue macrophages may be a source of proinflammatory factors and can regulate the secretory activity of adipocytes [88].”
BackgroundChen, X., Xiu, M., Xing, J., Yu, S., Min, D., & Guo, F. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479439 · Cited by 5,742
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“Disruption of antidepressant induced hippocampal neurogenesis by selective irradiation of the hippocampus also blocked the antidepressant effects of fluoxetine and imipramine [140], suggesting that neurogenesis is fundamental in determining the functional consequences of antidepressant treatment [138].”
BackgroundEuropean Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Adipocytokines: mediators linking adipose tissue, inflammation and immunity
Tilg, H., & Moschen, A. R. (2006) · Nature Reviews Immunology · doi:10.1038/nri1937 · Cited by 3,188 · cited 1×
“, leptin, adiponectin, and resistin) [33–35].”
Adipose Tissue, Inflammation, and Cardiovascular Disease
Berg, A. H., & Scherer, P. E. (2005) · Circulation Research · doi:10.1161/01.res.0000163635.62927.34 · Cited by 2,113 · cited 1×
“, leptin, adiponectin, and resistin) [33–35].”
Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways
Hardingham, G. E., Fukunaga, Y., & Bading, H. (2002) · Nature Neuroscience · doi:10.1038/nn835 · Cited by 1,686 · cited 7×
“This was found to be the case for serotonin 1A (5-HT1A) [121] and 5-HT1B [122] receptors, cannabinoid receptor subtype 1 (CB1R) [123], brain-derived neurotropic factor (BDNF) receptor, i.e., tropomyosin receptor kinase B (TrkB) [124–126], and the insulin receptor [104,127,128].”
BackgroundInfluentialFried, S. K., Bunkin, D. A., & Greenberg, A. S. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.3.4660 · Cited by 1,528
Glial reduction in the subgenual prefrontal cortex in mood disorders
Öngür, D., Drevets, W. C., & Price, J. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13290 · Cited by 1,525 · cited 1×
“The net result of these changes is loss of astrocytes and oligodendroglia and neuronal apoptosis, particularly in the subgenual prefrontal cortex, amygdala, and hippocampus, brain regions thought to be crucially involved in the genesis of the symptoms of depressive disorder [137].”
Background
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationAmare, A. T., Schubert, K. O., Klingler-Hoffmann, M., Cohen-Woods, S., & Baune, B. T. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.261 · Cited by 345
Effects of obesity on depression: A role for inflammation and the gut microbiota
Schachter, J., Martel, J., Lin, C.-S., Chang, C.-J., Wu, T.-R., Lu, C.-C., Ko, Y.-F., Lai, H.-C., Ojcius, D. M., & Young, J. D. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.08.026 · Cited by 253
“sion respond poorly to therapy, suggesting that obesity may reduce the efficacy of anti-depression treatment (Woo et al., 2016).”
BackgroundRole of Adiposity-Driven Inflammation in Depressive Morbidity
Capuron, L., Lasselin, J., & Castanon, N. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.123 · Cited by 182
“…(de Wit et al, 2010; Kasen et al, 2008; Ma and Xiao, 2010; Simon et al, 2008) and to predict recurrence of depressive episodes as well as antidepressant non-response in depressed patients (Kloiber et al, 2007; Nigatu et al, 2015; Oskooilar et al, 2009; Rizvi et al, 2014; Woo et al, 2016).”
BackgroundKetogenic diet as a metabolic therapy for mood disorders: Evidence and developments
Brietzke, E., Mansur, R. B., Subramaniapillai, M., Balanzá-Martínez, V., Vinberg, M., González-Pinto, A., Rosenblat, J. D., Ho, R., & McIntyre, R. S. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.07.020 · Cited by 173
Self-citationOuakinin, S. R. S., Barreira, D. P., & Gois, C. J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00431 · Cited by 125
Psychotropic Drug–Related Weight Gain and Its Treatment
McIntyre, R. S., Kwan, A. T. H., Rosenblat, J. D., Teopiz, K. M., & Mansur, R. B. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230922 · Cited by 113
Self-citationWu, F., Guo, X., Zhang, M., Ou, Z., Wu, D., Deng, L., Lü, Z., Zhang, J., Deng, G., Chen, S., et al. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102138 · Cited by 110
Vancassel, S., Capuron, L., & Castanon, N. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00499 · Cited by 94
Psychiatric Aspects of Obesity: A Narrative Review of Pathophysiology and Psychopathology
Weiss, F., Barbuti, M., Carignani, G., Calderone, A., Santini, F., Maremmani, I., & Perugi, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082344 · Cited by 113
“It has also been observed that obesity reduces the response of depressive disorders to antidepressant pharmacotherapy, but relevant results are less conclusive [68].”
Swainson, J., Reeson, M., Malik, U., Stefanuk, I., Cummins, M., & Sivapalan, S. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.094 · Cited by 105
Dodd, S., Mitchell, P. B., Bauer, M., Yatham, L., Young, A. H., Kennedy, S. H., Williams, L., Suppes, T., Lopez Jaramillo, C., Trivedi, M. H., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1379609 · Cited by 68
“There is also evidence that obesity is associated with decreased response to antidepressants (Kloiber et al. 2007; Woo et al. 2016).”
BackgroundSelf-citationDreimüller, N., Lieb, K., Tadić, A., Engelmann, J., Wollschläger, D., & Wagner, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.06.067 · Cited by 69
Ellul, P., Mariotti‐Ferrandiz, E., Leboyer, M., & Klatzmann, D. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00167 · Cited by 59
“Obese patients with MDD exhibit a poorer response to standard antidepressant treatments (90).”
BackgroundGay, F., Roméo, B., Martelli, C., Benyamina, A., & Hamdani, N. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113735 · Cited by 59
Qin, X., Wang, W., Wu, H., Liu, D., Wang, R., Xu, J., Jiang, H., & Pan, F. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104674 · Cited by 47
Avolio, E., Fazzari, G., Zizza, M., LORENZO, A. D., Renzo, L. D., Alò, R., Facciolo, R. M., & Canonaco, M. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.09.010 · Cited by 49
“Despite the introduction of new drugs for anxiety states, many obese patients treated for depression respond poorly to the therapy, suggesting that obesity states may interfere with the efficacy of the pharmacological treatment [41].”
Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder
Freeman, M. P., Hock, R. S., Papakostas, G. I., Judge, H., Cusin, C., Mathew, S. J., Sanacora, G., Iosifescu, D. V., DeBattista, C., Trivedi, M. H., et al. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001209 · Cited by 48
“Specifically, higher BMI may be associated with a lower or slower response to some antidepressant medications but not others,(10) although this finding is inconsistent and has not been the primary focus of studies in which this is reported.(11) Ketamine treatment for MDD has been increasingly studied and has becomemor…”
BackgroundPersonalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables
Perna, G., Alciati, A., Daccò, S., Grassi, M., & Caldirola, D. (2020) · Psychiatry Investigation · doi:10.30773/pi.2019.0289 · Cited by 43
Personalizing antidepressant choice by sex, body mass index, and symptom profile: An iSPOT-D report
Green, E., Goldstein‐Piekarski, A. N., Schatzberg, A. F., Rush, A. J., Ma, J., & Williams, L. M. (2016) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2016.12.001 · Cited by 46
Moussa, O., Ardissino, M., Kulatilake, P., Faraj, A., Muttoni, E., Darzi, A. W., Ziprin, P., Scholtz, S., & Purkayastha, S. (2019) · Clinical Obesity · doi:10.1111/cob.12305 · Cited by 36
Puzhko, S., Aboushawareb, S. A. E., Kudrina, I., Schuster, T., Barnett, T. A., Renoux, C., & Bartlett, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.113 · Cited by 38
Grigolon, R. B., Trevizol, A. P., Gerchman, F., Bambokian, A. D., Magee, T., McIntyre, R. S., Gomes, F. A., Brietzke, E., & Mansur, R. B. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.032 · Cited by 35
Self-citationKe, Y., Bu, S., Ma, H., Gao, L., Cai, Y., Zhang, Y., & Zhou, W. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01621 · Cited by 38
Brain Metabolic Alterations in Rats Showing Depression-Like and Obesity Phenotypes
Głombik, K., Detka, J., Góralska, J., Kurek, A., Solnica, B., & Budziszewska, B. (2019) · Neurotoxicity Research · doi:10.1007/s12640-019-00131-w · Cited by 33
González‐Castro, T. B., Escobar-Chan, Y. M., Fresán, A., López‐Narváez, M. L., Tovilla‐Zárate, C. A., Juárez‐Rojop, I. E., Blé‐Castillo, J. L., Mendoza, A. D. G., & Vázquez, P. I. A. (2019) · Journal of Health Psychology · doi:10.1177/1359105319876326 · Cited by 38
“In this sense, antidepressants (i.e. nortriptyline, paroxetine, mirtazapine, sertraline, doxepin, among others) are associated with a greater risk of weight gain (Woo et al., 2016).”
BackgroundCardinal, P., de Oliveira, C. M., Sauvant, J., Foury, A., Darnaudéry, M., Vancassel, S., Castanon, N., & Capuron, L. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02330-9 · Cited by 33
Amare, A. T., Schubert, K. O., Cohen‐Woods, S., & Baune, B. T. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/150615 · Cited by 29
McIntyre, R. S., Paron, E., Burrows, M., Blavignac, J., Gould, E. M., Camacho, F., & Barakat, M. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.04.017 · Cited by 27
Self-citationLiu, B., Ruz‐Maldonado, I., Toczyska, K., Olaniru, O. E., Zariwala, M. G., Hopkins, D., Zhao, M., & Persaud, S. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14791 · Cited by 23
Aleti, G., Kohn, J. N., Troyer, E. A., Weldon, K. C., Huang, S. W., Tripathi, A., Dorrestein, P. C., Swafford, A. D.-E., Knight, R. D., & Hong, S. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02483-4 · Cited by 23
“Despite the advent of antidepressant drugs and their long-term usage in clinical treatment, the majority of patients with depression are treatment-refractory, and obesity may further reduce the efficacy of antidepressants [8].”
BackgroundRashidian, H., Subramaniapillai, M., Park, C., Lipsitz, O., Zuckerman, H., Teopiz, K. M., Cao, B., Lee, Y. L., Gill, H., Ho, R., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.074 · Cited by 24
Self-citationKohn, J. N., Cabrera, Y., Dimitrov, S., Guay-Ross, N., Pruitt, C., Shaikh, F., & Hong, S. (2019) · International Journal of Obesity · doi:10.1038/s41366-019-0375-3 · Cited by 20
“Treating depression in obese individuals poses unique challenges, such as poorer antidepressant responses and more severe symptomatology [3].”
Wu, S., Chen, W.-J., Chang, J. P., Guu, T., Hsin, M.-C., Huang, C., Mischoulon, D., Capuron, L., & Su, K. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13061003 · Cited by 21
“Longterm follow-up studies have identified a higher risk of weight gain in individuals prescribed antidepressants, highlighting the need for personalized treatment approaches that consider an individual’s BMI or adiposity [50].”
BackgroundLin, Y., Cheng, S., Liu, W., Zailani, H., Wu, S., Hung, M., & Su, K. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.10.028 · Cited by 21
An augmentation study of MSI-195 (S-adenosylmethionine) in Major Depressive Disorder
Targum, S. D., Cameron, B. R., Ferreira, L., & MacDonald, I. D. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.10.010 · Cited by 18
Xiao, L., Zhou, J. L., Galling, B., Chen, R., & Wang, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.059 · Cited by 20
Tarabeih, N., Kalinkovich, A., Shalata, A., Cherny, S. S., & Livshits, G. (2022) · Journal of Pain Research · doi:10.2147/jpr.s349251 · Cited by 18
“In addition, antidepressants and most antipsychotics are found to induce weight gain.(70,77) Obesity measures, especially anthropometrical measurements, eg, BMI and WHR, have been repeatedly associated with LBP.”
BackgroundWoo, Y. S., Bahk, W., Seo, J. S., Park, Y., Kim, W., Jeong, J., Shim, S.-H., Lee, J. G., Jang, S.-H., Yang, C.-M., et al. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.1.37 · Cited by 19
“treatment improvement, depressive episode characteristics, and patient characteristics [5-9].”
BackgroundSelf-citationDisrupting the Mood and Obesity Cycle: The Potential Role of Metformin
Doan, S. N., Patel, S. K., Xie, B., Nelson, R. A., & Yee, L. D. (2023) · Obesities · doi:10.3390/obesities3010006 · Cited by 17
“Additionally, pharmaceutical treatments for mood disorders can also induce weight gain [28,39–41], with potential to exacerbate insulin resistance and the inexorable cycle of mood and metabolic dysfunction [42,43].”
BackgroundChang, J. P., Iqbal, A. Z., Do, Q. L., Yaseen, M., Wu, S., Malau, I. A., Zailani, H., & Su, K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107857 · Cited by 14
den Uil, M. G., Hut, H. W., Wagelaar, K. R., Abdullah-Koolmees, H., Cahn, W., Wilting, I., & Deneer, V. H. M. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1249164 · Cited by 13
“Obesity and psychiatric disease have a complex bidirectional relationship (Holt and Peveler, 2009; Woo et al., 2016).”
BackgroundOverweight in mood disorders: Effects on morbidity and treatment response
Miola, A., Pinna, M., Manchia, M., Tondo, L., & Baldessarini, R. J. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.032 · Cited by 13
Ziemens, D., Touma, C., & Rappeneau, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147952 · Cited by 15
Leptin, obesity, and response to ketamine
Rashidian, H., Rosenblat, J. D., McIntyre, R. S., & Mansur, R. B. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109773 · Cited by 12
Self-citationHitzler, M., Karabatsiakis, A., & Kolassa, I. (2019) · Psychotherapeut · doi:10.1007/s00278-019-0366-9 · Cited by 15
Managing comorbid obesity and depression through clinical pharmacotherapies
McElroy, S. L., Guerdjikova, A. I., Mori, N. N., & Keck, P. E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1198776 · Cited by 11
“ably to pharmacotherapy as compared to nonobese patients [35,61].”
BackgroundTreating obesity in patients with depression: a narrative review and treatment recommendation
Kushner, P. R., Kahan, S. I., & McIntyre, R. S. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2478812 · Cited by 10
“There are also considerable overlapping public health factors that impact the patient’s experience and may be responsible for the heterogenous response to treatment commonly seen in patients with both obesity and depression [19,61,62].”
Self-citationPuzhko, S., Schuster, T., Barnett, T. A., Renoux, C., Rosenberg, E., Barber, D., & Bartlett, G. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00024 · Cited by 7
“Different response to certain groups and types of AD in patients with excess weight, as compared to normal weight patients, was reported in several studies and described in two recent reviews (6, 41).”
BackgroundResultObesity and Depression: Shared Pathophysiology and Translational Implications
Huet, L., Delgado, I., Aouizerate, B., Castanon, N., & Capuron, L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00016-0 · Cited by 12
Castanon, N., Vancassel, S., Amadieu, C., Cussotto, S., Leyrolle, Q., Lucas, C., Lefèvre, A., Emond, P., Dinel, A., & Capuron, L. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106107 · Cited by 9
Machine Learning in Electroconvulsive Therapy: A Systematic Review
Lundin, R. M., Falcão, V. P., Kannangara, S., Eakin, C. W., Abdar, M., OʼNEILL, J. F., Khosravi, A., Eyre, H. A., Nahavandi, S., Loo, C. K. A., et al. (2024) · Journal of Ect · doi:10.1097/yct.0000000000001009 · Cited by 9
Iyiewuare, P. O., Rohan, K. J., & Postolache, T. T. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.08.154 · Cited by 6
Puzhko, S., Schuster, T., Barnett, T. A., Renoux, C., Munro, K., Barber, D., & Bartlett, G. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.08.018 · Cited by 6
Abdelaziz, H. A., Abdelbaki, T. N., Dean, Y. E., & Assem, S. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05160-6 · Cited by 6
“Many obese patients treated for depression respond poorly to therapy, suggesting that obesity may reduce the efficacy of antidepressant treatment [21].”
BackgroundTreating Depression in the Era of Precision Medicine: Challenges and Perspectives
Musker, M., & Wong, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813333-0.00023-8 · Cited by 6
Impact of morbid obesity on treatment outcome in a clinical trial of major depressive disorder
Targum, S. D., & Catania, C. J. (2017) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2017.06.002 · Cited by 5
Poor muscle health and cardiometabolic risks associated with antidepressant treatment
Andersson, P., Linge, J., Gurholt, T. P., Sønderby, I. E., Hindley, G., Andreassen, O. A., & Leinhard, O. D. (2024) · Obesity · doi:10.1002/oby.24085 · Cited by 4
“In addition, changes in body composition and fat distribution from AD usage can, in turn,affectpharmacokineticsandtreatmentresponse[26,27].”
Hu, J., Li, X., Tang, M., Wan, M., Zhang, S., Wu, H., Li, M., Wang, L., Xiao, H., Zhu, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-96268-0 · Cited by 4
“Interestingly, some studies have found that individuals with a body mass index ≥ 25 achieve a poorer clinical response to antidepressant treatment 31 , and that treatment-resistant depression is associated with baseline obesity 32 .”
The Link Between Obesity and Depression: Exploring Shared Mechanisms
Woo, Y. S., & Bahk, W. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_15 · Cited by 3
Self-citationBALKOCA, F., Çubukçu, M., & Yurt, N. Ş. (2023) · Turkish Journal of Diabetes and Obesity · doi:10.25048/tudod.1323889 · Cited by 7
Syed, O. A., Sobolenko, V., Nestor, S. M., Husain, M. I., Lipsman, N., Alam, F., & Giacobbe, P. (2026) · CNS Drugs · doi:10.1007/s40263-026-01296-7 · Cited by 2
Genetic Overlap Between Depression and Cardiometabolic Disorders
Amare, A. T., Schubert, K. O., & Baune, B. T. (2016) · Springer eBooks · doi:10.1007/978-3-319-32480-7_15
Impacts of Mindfulness and Physical Activity on Depression
Monceaux, J., Yepez, M., Ulliman, J., & Parajes, K. (2019)
Posttraumatic Stress Disorder and Incident Type 2 Diabetes: Is Obesity to Blame?
Scherrer, J. F., & Lustman, P. J. (2019) · Chronic Stress · doi:10.1177/2470547019863415 · Cited by 2
“The latter phenomenon may be due to obesity-associated inflammation that interferes with antidepressant medication effects.(11) Another barrier to weight loss in PTSD and depression is a dysregulated physiological stress response (e.”
BackgroundFactors affecting development of depression in overfood and obesity people
Jandrić−Kočić, M. (2020) · Medicinski casopis · doi:10.5937/mckg54-26015
Hong, S., Aleti, G., Kohn, J. N., Troyer, E. A., Weldon, K. C., Huang, S. W., Tripathi, A., Dorrestein, P. C., Swafford, A. D.-E., & Knight, R. D. (2021) · Research Square · doi:10.21203/rs.3.rs-829379/v1
Rajkumar, R. P. (2023) · International Journal of Translational Medicine · doi:10.3390/ijtm3010012 · Cited by 3
“Obesity is associated with a poorer response to antidepressant treatment in depressed patients [15,16], whereas weight loss leads to an improvement in depressive symptoms [17], but this is often difficult to accomplish in practice.”
BackgroundLin, K., Hasegawa, K., Rapelli, V. R., Yang, J., Parsey, R. V., & DeLorenzo, C. (2025) · Research Square · doi:10.21203/rs.3.rs-6257703/v1
Modeling treatment-resistant depression in the preclinical setting
Tye, S. J., Yates, C. G., & Postorivo, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00005-0
Lifestyle interventions for treatment-resistant depression
Toups, M. S. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00038-4
Howard, D. M., Gilchrist, L., Proitsi, P., Paul, E. R., Heilig, M. A., Östman, L., Kämpe, R., & Hamilton, J. P. (2025) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2025.101144 · Cited by 2
“This position is supported, in part, by findings that overweight and obese individuals are less likely to benefit from antidepressant therapy (Woo et al., 2016).”
Lin, K., Hasegawa, K., Rapelli, V. R., Yang, J., Parsey, R. V., & DeLorenzo, C. (2026) · Scientific Reports · doi:10.1038/s41598-026-43078-7
Etude de la voie de la kynurénine dans la symptomatologie du sujet obèse
Huet, L. (2019) · theses.fr (ABES) · doi:10.70675/ff26d7c8z4c5fz4c86z9e6ezd8d843268447 · Cited by 2
de Oliveira, C. M. (2021) · theses.fr (ABES) · doi:10.70675/7291a4e5z9949z4fd4za27dze7f18385347b · Cited by 2
Hong, S., Kohn, J. N., Dimitrov, S., Pruitt, C. S., Cheng, T., & Shaikh, F. (2026) · NeuroImmunoModulation · doi:10.1159/000552352
Woo, Y. S., & Kwon, Y. (2026) · Springer eBooks · doi:10.1007/978-981-92-1331-3_10
Self-citationMechlińska, A., Wiglusz, M. S., Słupski, J., Pastuszak, K., & Cubała, W. J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1858899
Metadata
- Authors
- Woo, Y., Seo, H.-J., McIntyre, R., & Bahk, W.-M.
- Affiliations
- University Health Network (CA)
- Catholic University of Korea (KR)
- Corresponding author
- Bahk, Won-Myong
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-01-12
- Volume
- 17
- Issue
- 1
- Pages
- 80
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC4730324
- OpenAlex
- W2237079496
- Cited by
- 79
- References
- 177
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 4 · 2023: 9 · 2022: 7 · 2021: 9 · 2020: 10 · 2019: 13 · 2018: 6 · 2017: 6 · 2016: 4
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Brain and Behavior Research Foundation
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sunovion
- H. Lundbeck A/S
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Social Sciences › Psychology › Clinical Psychology › Eating Disorders and Behaviors
- Keywords
- obesity, depressive disorders, antidepressant response, overweight, sex differences, menopausal status, inflammatory markers, neuropsychological performance, antidepressant efficacy
- MeSH terms
- Adult, Age Factors, Antidepressive Agents, Clinical Trials as Topic, Depressive Disorder, Female, Humans, Male, Middle Aged, Obesity, Prognosis, Sex Factors, Body Mass Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.